针对肥胖和2型糖尿病的基于的治疗方法的最新进展
Clifford J Bailey1, Peter R Flatt2, J Michael Conlon2
1Life and Health Sciences, Aston University, Birmingham B4 7ET, UK.
Peptides
|January 6, 2024
概括
新的基于英克雷丁的类疗法,包括GLP-1受体激动剂 (如西马格卢提德) 和双重激动剂 (如蒂尔泽帕提德),在治疗2型糖尿病和肥胖症方面取得了显著的成功. 这些疗法有效降低血糖和体重,有证据表明有心血管益处.
科学领域:
- 内分泌学和新陈代谢学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 二型糖尿病 (T2DM) 和肥胖症是全球重大健康挑战.
- 最近基于基蛋白的类疗法取得的进展扩大了治疗选择.
研究的目的:
- 审查T2DM和肥胖症的新型基于隐素的类疗法的疗效和潜在益处.
- 要突出像西马格卢提德和蒂尔泽帕提德这样的药物对血糖控制和减肥的影响.
主要方法:
- 对GLP-1受体激动剂 (赛马格卢提德) 和双GLP-1/GIP激动剂 (蒂尔泽帕提德) 的大型临床试验数据的分析.
- 审查新兴疗法,包括三重激动剂和组合疗法 (例如CagriSema).
- 评估报告的降低HbA1c和体重的疗效,以及潜在的心脏脏保护作用.
主要成果:
- 塞马格卢提德和蒂尔泽帕提德显著降低了HbA1c (>2%) 和体重 (>10%在T2DM中,>15%在肥胖个体中).
- 新兴的疗法,如雷达和CagriSema,显示出强大的疗效.
- 胃肠道不良反应通常是轻度至中度且过时的,尽管在某些患者中会出现治疗停止.
结论:
- 基于因克雷丁的类疗法在治疗T2DM和肥胖症方面取得了重大进展.
- 这些疗法在血糖控制和体重管理方面提供了显著的改善.
- 对新药及其长期益处进行进一步的研究是有必要的.
相关概念视频
01:24Glucagon-like Receptor Agonists
325
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
325
01:15Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
01:16Insulin: Dosing Regimen and Adverse Effects
176
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
176
01:22Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
01:36Carbohydrate Metabolism
11.1K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.1K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
206
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
206